Cullinan Therapeutics CGEM
NASDAQ CGEM
$14.89 +0.00 (+0.00%)
As of: Oct 22, 2026 · 2:30 PM EDT

Cullinan Therapeutics (CGEM) Non-Current Debt (2022)

Updated

Analysis

Cullinan Therapeutics (CGEM) Non-Current Debt (2022) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Debt (Qtr)
1 Eli Lilly 1,171.69 Bn 1,140.28 Bn 19.71 Bn 47.86 Bn
2 Johnson & Johnson 649.22 Bn 569.08 Bn 17.30 Bn 35.80 Bn
3 AbbVie 504.17 Bn 477.29 Bn 12.70 Bn 62.48 Bn
4 Merck 366.35 Bn 320.73 Bn 12.21 Bn 51.08 Bn
5 Novartis Ag 303.54 Bn 267.53 Bn 11.24 Bn 1.96 Bn
6 Astrazeneca 269.49 Bn 243.18 Bn 12.86 Bn 23.68 Bn
7 Amgen 242.61 Bn 198.01 Bn 7.24 Bn 51.86 Bn
8 Gilead Sciences 195.09 Bn 169.29 Bn 6.22 Bn 23.83 Bn
9 Pfizer 172.48 Bn 119.12 Bn 10.94 Bn 60.50 Bn
10 Cullinan Therapeutics 928.65 Mn 594.15 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2022 1.40 Mn
Mar 31, 2022 800,000.00
API Access

Cullinan Therapeutics Non-Current Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-current-debt&ticker=CGEM&period=max&api_key=YOUR_API_KEY